Skip Navigation

JNCI Journal of the National Cancer Institute 2002 94(20):1520-1521; doi:10.1093/jnci/94.20.1520
© 2002 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Twombly, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Twombly, R.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 94, No. 20, 1520-1521, October 16, 2002
© 2002 Oxford University Press

NEWS

First Clinical Trials of Endostatin Yield Lukewarm Results

Renee Twombly

The first 10% of the full text of this article appears below.

By the strictest criteria, the antiangiogenesis drug endostatin has passed muster in its first two phase I clinical trials in cancer patients, which were formally published last month. Those trials proved that endostatin is a very safe drug, even at a variety of doses—a masterful jump over the first testing hurdle.

But now that these first human tests have been reported, the issue of whether the agent—known as recombinant human endostatin (rh-Endo) and once heralded as a likely cure for cancer—has any beneficial effect looms larger than ever. In fact, researchers at the two institutions that conducted the trials, the Dana Farber . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 DMMHome page
A. Gopinathan and D. A. Tuveson
The use of GEM models for experimental cancer therapeutics
Dis. Model. Mech., September 1, 2008; 1(2-3): 83 - 86.
[Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
X.-P. Li, C. Y.S. Li, X. Li, Y. Ding, L. L.Y. Chan, P.-H. Yang, G. Li, X. Liu, J. S. Lin, J. Wang, et al.
Inhibition of human nasopharyngeal carcinoma growth and metastasis in mice by adenovirus-associated virus-mediated expression of human endostatin
Mol. Cancer Ther., May 1, 2006; 5(5): 1290 - 1298.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. Ponnazhagan, G. Mahendra, S. Kumar, D. R. Shaw, C. R. Stockard, W. E. Grizzle, and S. Meleth
Adeno-Associated Virus 2-Mediated Antiangiogenic Cancer Gene Therapy: Long-Term Efficacy of a Vector Encoding Angiostatin and Endostatin over Vectors Encoding a Single Factor
Cancer Res., March 1, 2004; 64(5): 1781 - 1787.
[Abstract] [Full Text] [PDF]

Home page
 JEMHome page
X. Hong, L. Lei, and R. Glas
Tumors Acquire Inhibitor of Apoptosis Protein (IAP)-mediated Apoptosis Resistance through Altered Specificity of Cytosolic Proteolysis
J. Exp. Med., June 16, 2003; 197(12): 1731 - 1743.
[Abstract] [Full Text] [PDF]